Results from studies involving Amgen's oncology portfolio will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 29-June 2.
Abstracts are available on the ASCO website at http://am.asco.org/abstracts and updated data will be presented at the meeting.
If you are at ASCO, stop by Amgen's booth #18041 to learn more about Amgen Oncology.
Follow Amgen on Twitter at http://twitter.com/amgen to receive news updates during ASCO.
|June 1, 2015||Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors|
|May 13, 2015||Amgen Data At ASCO 2015 Highlight Oncology Pipeline And Portfolio|